Moderna (NASDAQ: MRNA) shares closed Friday, June 26, with a strong surge of 12%. Over the past six months, the stock price of the American biotech giant has soared 125.51% from lows near $46 recorded in early June. Behind this impressive rally lies not one, but several fundamental catalysts.

Key Risk Eliminated: Unanimous FDA Support

The key driver was the decision by the FDA's Vaccines and Related Biological Products Advisory Committee. On June 18, the committee unanimously (9 out of 9 votes) supported a positive assessment of mFLUSIVA (mRNA-1010), an experimental seasonal influenza vaccine for individuals over 50. Unanimous decisions at this level in biotech are extremely rare, and this virtually eliminated regulatory uncertainty ahead of the final verdict expected on August 5.

If approved, mFLUSIVA would become the first seasonal influenza vaccine based on mRNA technology in the U.S. This is not just a breakthrough for Moderna—it opens a new market segment that could fundamentally reshape its revenue structure.

Wall Street Remains Cautious but Raises Targets

Despite the euphoria, analysts remain restrained. Piper Sandler raised its price target to $77, and Jefferies to $53, maintaining a "hold" rating. The median forecast for MRNA stands at $43.45—significantly below current trading levels. Insider selling dominates the market: 75 of the latest transactions were sell-offs. Most experts expect significant revenue growth from flu vaccine sales to begin no earlier than 2027.

Beyond Vaccines: Reorganization and Oncology

Moderna is not limiting itself to flu. The company has reorganized its business structure around three areas: vaccines, oncology, and rare diseases. This news alone lifted shares by 6.3%. On June 25, at the Science Day event, management presented an expanded development portfolio, including programs for in vivo CAR-T and T-cell engineering for oncology and autoimmune diseases.

Additional momentum came from plans to invest in production in Germany, including sites that BioNTech intends to close. Over several trading sessions, this added 8–12% to the stock. The market viewed this move as a long-term bet on increasing capacity ahead of a wave of new launches in 2027–2028.

My analysis: Moderna's rally is not a speculative bubble but a meaningful asset revaluation. The unanimous FDA support for the flu vaccine removes the main regulatory risk, while the business reorganization and focus on oncology create a long-term narrative. However, current valuations already price in a significant portion of future successes. Investors should closely watch the FDA decision on August 5—it will be the key trigger for the next move, whether a continuation of the rally or a correction.